Tofflon Itema

Tofflon Itema serves as a strategic reference point for the European and American markets, providing innovative solutions and applications in the field of industrial lyophilizers for the medical and biopharmaceutical sectors.

The Tofflon Itema facility in Novara established in 2023, a state-of-the-art manufacturing plant distinguished by its high standards of quality and innovation, produces advanced lyophilization systems to produce antibiotics, vaccines, diagnostic drugs, protein-based formulations, and biotechnological products.

From research to large-scale manufacturing, Tofflon Itema accelerates advancements in pharma and bioscience through integrated solutions and cutting-edge technologies, shaping the next generation of biopharmaceutical production through innovation, systematization, and global reach.

The company’s expertise is structured across four main divisions — Bioprocess, Formulation Equipment, Engineering, and Food Engineering — working synergistically to support dynamic biotechnology breakthrough.

Founded as a joint venture between Tofflon Science and Technology Group, an Asian industrial leader in the pharmaceutical sector, and Itema Group, a global provider of advanced weaving machinery and integrated solutions, Tofflon Itema represents the convergence of technological excellence and industrial innovation.